BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 33726684)

  • 1. Frequent high-risk HPV co-infections excluding types 16 or 18 in cervical neoplasia in Guadeloupe.
    Gaete S; Auguste A; Bhakkan B; Peruvien J; Herrmann-Storck C; Socrier Y; Diedhiou A; Deloumeaux J
    BMC Cancer; 2021 Mar; 21(1):281. PubMed ID: 33726684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence and genotyping of high risk human papillomavirus in cervical cancer samples from Punjab, Pakistan.
    Siddiqa A; Zainab M; Qadri I; Bhatti MF; Parish JL
    Viruses; 2014 Jul; 6(7):2762-77. PubMed ID: 25036463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papilloma virus infection of uterine cervix and spectrum of cervical pathology in human immunodeficiency virus/AIDS.
    Jain BB; Adhikary T; Sadhukhan PC; Nandi A
    J Cancer Res Ther; 2021; 17(6):1462-1467. PubMed ID: 34916378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genotype distribution of human papillomavirus (HPV) in histological sections of cervical intraepithelial neoplasia and invasive cervical carcinoma in Madrid, Spain.
    García-Espinosa B; Moro-Rodríguez E; Alvarez-Fernández E
    BMC Cancer; 2012 Nov; 12():533. PubMed ID: 23167826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada.
    Coutlée F; Ratnam S; Ramanakumar AV; Insinga RR; Bentley J; Escott N; Ghatage P; Koushik A; Ferenczy A; Franco EL
    J Med Virol; 2011 Jun; 83(6):1034-41. PubMed ID: 21503917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of the effectiveness of HPV16/18 infection referred for colposcopy in cervical cancer screening in Northwest of China.
    Zhang Q; Zhao M; Cao D; Wei X; Wang L; Li Y; Yang T; Zhao J; Pei M; Jia H; Cao S; Quan S; Yang X
    J Med Virol; 2018 Jan; 90(1):165-171. PubMed ID: 28710863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence.
    Kjær SK; Frederiksen K; Munk C; Iftner T
    J Natl Cancer Inst; 2010 Oct; 102(19):1478-88. PubMed ID: 20841605
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of the AS04-Adjuvanted HPV16/18 Vaccine: Pooled Analysis of the Costa Rica Vaccine and PATRICIA Randomized Controlled Trials.
    Tota JE; Struyf F; Sampson JN; Gonzalez P; Ryser M; Herrero R; Schussler J; Karkada N; Rodriguez AC; Folschweiller N; Porras C; Schiffman M; Schiller JT; Quint W; Kreimer AR; Wheeler CM; Hildesheim A;
    J Natl Cancer Inst; 2020 Aug; 112(8):818-828. PubMed ID: 31697384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of high-risk human papilloma virus genotypes and associated risk of cervical precancerous lesions in a large U.S. screening population: data from the ATHENA trial.
    Monsonego J; Cox JT; Behrens C; Sandri M; Franco EL; Yap PS; Huh W
    Gynecol Oncol; 2015 Apr; 137(1):47-54. PubMed ID: 25667973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HPV prevalence and type-distribution in cervical cancer and premalignant lesions of the cervix: A population-based study from Northern Ireland.
    Anderson LA; O'Rorke MA; Wilson R; Jamison J; Gavin AT;
    J Med Virol; 2016 Jul; 88(7):1262-70. PubMed ID: 26680281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-infections of HPV16/18 with other high-risk HPV types and the risk of cervical carcinogenesis: A large population-based study.
    Wu P; Xiong H; Yang M; Li L; Wu P; Lazare C; Cao C; Gao P; Meng Y; Zhi W; Lin S; Hu J; Wei J; Ma D; Liu J; Yin P; Xing H
    Gynecol Oncol; 2019 Dec; 155(3):436-443. PubMed ID: 31604662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States.
    Wheeler CM; Hunt WC; Joste NE; Key CR; Quint WG; Castle PE
    J Natl Cancer Inst; 2009 Apr; 101(7):475-87. PubMed ID: 19318628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Type-specific human papillomavirus prevalence in cervical intraepithelial neoplasia and cancer in Iran.
    Heydari N; Oskouee MA; Vaezi T; Shoja Z; Esmaeili HA; Hamkar R; Shahmahmoodi S; Jalilvand S
    J Med Virol; 2018 Jan; 90(1):172-176. PubMed ID: 28786495
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of human papillomavirus types in high-grade cervical intraepithelial neoplasia and cancer in Italy.
    Carozzi FM; Tornesello ML; Burroni E; Loquercio G; Carillo G; Angeloni C; Scalisi A; Macis R; Chini F; Buonaguro FM; Giorgi Rossi P;
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2389-400. PubMed ID: 20826836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cervical adenocarcinoma in situ: Human papillomavirus types and incidence trends in five states, 2008-2015.
    Cleveland AA; Gargano JW; Park IU; Griffin MR; Niccolai LM; Powell M; Bennett NM; Saadeh K; Pemmaraju M; Higgins K; Ehlers S; Scahill M; Johnson Jones ML; Querec T; Markowitz LE; Unger ER;
    Int J Cancer; 2020 Feb; 146(3):810-818. PubMed ID: 30980692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distribution of HPV Genotype in Invasive Cervical Carcinoma and Cervical Intraepithelial Neoplasia in Zhejiang Province, Southeast China: Establishing the Baseline for Surveillance.
    Xu XX; Zhou JS; Yuan SH; Yu H; Lou HM
    Int J Environ Res Public Health; 2015 Sep; 12(9):10794-805. PubMed ID: 26404339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of
    Lehtinen M; Lagheden C; Luostarinen T; Eriksson T; Apter D; Harjula K; Kuortti M; Natunen K; Palmroth J; Petäjä T; Pukkala E; Siitari-Mattila M; Struyf F; Nieminen P; Paavonen J; Dubin G; Dillner J
    BMJ Open; 2017 Aug; 7(8):e015867. PubMed ID: 28821519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.
    Lehtinen M; Paavonen J; Wheeler CM; Jaisamrarn U; Garland SM; Castellsagué X; Skinner SR; Apter D; Naud P; Salmerón J; Chow SN; Kitchener H; Teixeira JC; Hedrick J; Limson G; Szarewski A; Romanowski B; Aoki FY; Schwarz TF; Poppe WA; De Carvalho NS; Germar MJ; Peters K; Mindel A; De Sutter P; Bosch FX; David MP; Descamps D; Struyf F; Dubin G;
    Lancet Oncol; 2012 Jan; 13(1):89-99. PubMed ID: 22075171
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence of Human Papillomavirus Genotypes Among Women With High-Grade Cervical Lesions in Beijing, China.
    Xiao M; Xu Q; Li H; Gao H; Bie Y; Zhang Z
    Medicine (Baltimore); 2016 Jan; 95(3):e2555. PubMed ID: 26817906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-risk human papillomavirus genotype distribution and attribution to cervical cancer and precancerous lesions in a rural Chinese population.
    Zhao XL; Hu SY; Zhang Q; Dong L; Feng RM; Han R; Zhao FH
    J Gynecol Oncol; 2017 Jul; 28(4):e30. PubMed ID: 28541628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.